evipedia.ai
← Back

Mastic Gum for Health & Longevity

Evidence Review created on 10/22/2026 using AI4L / Opus 5.5

Also known as: Mastic, Mastiha, Masticha, Mastix, Gum Mastic, Chios Mastic Gum, Chios Mastiha, Mastic Resin, Tears of Chios, Pistacia lentiscus Resin, Lentisk Resin, Damla Sakızı

Motivation

Mastic gum, also called mastiha, is the fragrant resin that seeps from the bark of the mastic tree, a shrub tapped for this purpose almost only on the Greek island of Chios. It is chewed as a natural gum, used to flavor food and drinks, and sold as powder and capsules. Interest comes from its long history as a stomach remedy and from plant compounds studied for their activity against certain bacteria and inflammation.

Mastic has been used for indigestion and mouth care for more than two thousand years. From the 1980s onward, small hospital studies of stomach ulcers and laboratory work on an ulcer-linked stomach bacterium drew medical attention, and Greek research groups have since studied it for digestive and metabolic health. The European medicines regulator lists it as a traditional herbal remedy for mild indigestion.

This review examines the human evidence for and against mastic gum as a health and longevity intervention for proactive adults: its effects on digestive, oral and metabolic health, its safety, the doses used in trials, and how strongly the research base, including who funded it, supports each claim.

Benefits - Risks - Protocol - Conclusion

This section lists high-level reviews that discuss mastic gum in depth.

Four items qualified; other candidate content either mentioned mastic only briefly or could not be retrieved for verification. Of the priority experts, only Chris Kresser and Andrew Huberman mention mastic, and only briefly: Kresser devotes one paragraph of a heartburn article to mastic against Helicobacter pylori (the stomach bacterium linked to ulcers) (Get Rid of Heartburn and GERD Forever in Three Simple Steps; GERD: chronic acid reflux), and Huberman’s guest mentions mastic gum in passing as a jaw-training gum (How to Improve Your Teeth & Oral Microbiome for Brain & Body Health – Dr. Staci Whitman). Neither discusses mastic in enough depth to be listed above. Web and on-site searches found no content on mastic from Rhonda Patrick, Peter Attia, Life Extension Magazine or Lifespan.io.

Grokipedia

  • Mastic (plant resin)

    An encyclopedic overview of mastic’s botany, Chios harvesting, history, chemistry and traditional medical uses, useful for background rather than for weighing clinical evidence.

Examine

No dedicated Examine article on mastic gum exists. Examine covers mastiha only through two members-only research-feed study summaries, which are not a primary page for the intervention.

ConsumerLab

No dedicated ConsumerLab article or product review on mastic gum exists. Mastic appears only within members-only CL Answers on peptic ulcers, acid reflux and irritable bowel syndrome.

Systematic Reviews

This section lists systematic reviews that assess mastic in digestive and oral conditions.

No systematic review or meta-analysis of mastic’s adverse effects exists, so the principal risk side of the trade-off is unrepresented in this section.

Mechanism of Action

Mastic is a complex resin, not a single compound. About 70% is triterpenes (large plant compounds, chiefly masticadienonic and isomasticadienonic acids) (Brieudes et al., 2021); the rest includes an insoluble natural polymer and a volatile oil rich in α-pinene and myrcene (Pachi et al., 2020). Proposed mechanisms:

  • Antibacterial action: triterpenic acids kill H. pylori in laboratory tests (Paraschos et al., 2007).
  • Anti-inflammatory signalling: mastic suppresses NF-κB (a master switch for inflammatory genes) in cancer cells (He et al., 2007).
  • Metabolic targets: its acids inhibit 11β-HSD1 (an enzyme that regenerates active cortisol inside tissues) (Vuorinen et al., 2015), a paper citing earlier reports that oleanonic acid activates PPAR-γ (a receptor governing fat storage and insulin sensitivity).
  • Immune effects: mastic sugar-protein complexes blunted neutrophil (white blood cell) activation by an H. pylori protein (Kottakis et al., 2009).

The competing view: laboratory potency translates poorly into the body; mastic failed to clear H. pylori from infected mice (Loughlin et al., 2003), possibly because the polymer limits solubility.

As a whole resin, mastic has no established half-life, selectivity, tissue distribution or metabolic pathway. Terpenes appear in blood within 30 minutes and peak at 2–4 hours (Papada et al., 2018), in a study co-authored by a researcher affiliated with the Chios Mastic Gum Growers Association, the producers’ cooperative with a direct financial interest in mastic sales; many Greek trials cited below share this co-authorship. A rat study found no induction of CYP1A1/CYP1A2 (liver enzymes that process many drugs) (Katsanou et al., 2014).

Historical Context & Evolution

Mastic has been harvested on Chios for about 2,500 years; Dioscorides and Galen described its use for stomach complaints (Pachi et al., 2020). Its modern medical consideration began with small clinical studies:

  • Ulcer trials (1984–1986): a double-blind trial in 38 people with duodenal ulcer (an ulcer in the first part of the small intestine) reported endoscopic healing in 70% on 1 g/day mastic versus 22% on placebo after 2 weeks (Al-Habbal et al., 1984), followed by a small report in benign gastric ulcer (Huwez & Al-Habbal, 1986).
  • The H. pylori hypothesis (1998): a letter in the New England Journal of Medicine reported that mastic killed H. pylori strains in the laboratory (Huwez et al., 1998).
  • Mixed replication (2003–2010): Nottingham researchers found no reduction of the bacterium in eight patients (Bebb et al., 2003), while a Chios hospital pilot reported eradication in about one-third of patients (Dabos et al., 2010).
  • Broadening research (2007 onward): Athens groups extended trials to bowel inflammation, cholesterol, fatty liver and blood pressure, and in 2016 the EMA (European Medicines Agency) adopted an EU herbal monograph recognizing traditional use for mild indigestion and minor skin inflammation (EMA mastic page).

The positive and negative H. pylori studies differed in dose, duration and patient selection, and no large trial has resolved the question; the ulcer trials also predate routine H. pylori testing. Newer trials, pointing in both directions, focus on gut symptoms and metabolic markers.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: each placebo-controlled human symptom trial comes from a single research group, and the replications are unblinded, active-controlled or contradicted.

Medium 🟩 🟩

Relief of Functional Dyspepsia Symptoms

Functional dyspepsia (recurring upper-abdominal pain, fullness or burning without a structural cause) is mastic’s best-studied use. A placebo-controlled randomized trial of 148 patients from Dabos’s Chios hospital group used 350 mg three times daily for 3 weeks (Dabos et al., 2010). An unblinded crossover trial from Kaliora’s Athens group, compared with a no-treatment period, also reported relief (Kleftaki et al., 2025). A Cochrane review rated the evidence low-certainty (Báez et al., 2023).

Magnitude: Marked improvement in 77% on mastic versus 40% on placebo (Dabos et al., 2010); standardized mean difference (effect size in standard-deviation units) −0.33 versus placebo, 95% confidence interval (range of plausible true values) −0.66 to −0.01 (Báez et al., 2023).

Healing of Duodenal Ulcers

In a double-blind trial by Al-Habbal and Huwez, 38 people with endoscopically confirmed duodenal ulcer took 1 g/day mastic or lactose placebo for 2 weeks; mastic improved symptoms and endoscopic healing without reported side effects (Al-Habbal et al., 1984). The trial predates routine H. pylori testing and modern acid-suppressing drugs and has never been replicated, so its relevance to current care is uncertain.

Magnitude: Endoscopic healing in 70% (14/20) on mastic versus 22% (4/18) on placebo; symptom relief in 80% versus 50% (Al-Habbal et al., 1984).

Reduced Dental Plaque and Gum Inflammation ⚠️ Conflicted

Chewing mastic gum reduced salivary bacteria, new plaque and gum inflammation versus placebo gum in a small double-blind Japanese trial without brushing (Takahashi et al., 2003), and lowered salivary Streptococcus mutans (a main cavity-causing bacterium) versus paraffin in Turkish orthodontic patients (Aksoy et al., 2007). An Athens mastic toothpaste trial improved plaque and gum indices (Alexiou et al., 2025); a mastic mouthwash trial did not (Tsironi et al., 2023). Net: a plausible short-term antiplaque effect resting on small trials.

Magnitude: Plaque index 0.46 points lower (2.69 versus 3.15) and gingival (gum inflammation) index 0.22 points lower (0.44 versus 0.66) than placebo gum after 7 days without brushing (Takahashi et al., 2003).

Low 🟩

Lower Blood Lipids ⚠️ Conflicted

Crude mastic 1 g/day lowered total cholesterol but not LDL (artery-clogging cholesterol) or triglycerides (Kartalis et al., 2016); 5 g/day lowered cholesterol without placebo (Triantafyllou et al., 2007) and triglycerides versus placebo (Fukazawa et al., 2018). HYPER-MASTIC found lipids unchanged (Kalafati et al., 2026). Net: inconsistent.

Magnitude: Total cholesterol fell by 11.5 mg/dL with 1 g/day crude mastic over 8 weeks (13.5 mg/dL in those with BMI (body mass index) above 25), adjusted for age, sex, BMI and baseline values, with no significant change on 2 g/day crude powder; the abstract reports only the mastic-arm change, with no placebo-arm figure, so it is not compared between groups (Kartalis et al., 2016).

Lower Fasting Glucose and Insulin ⚠️ Conflicted

Crude mastic 1 g/day lowered fasting glucose over 8 weeks (Kartalis et al., 2016), and 5 g/day lowered insulin versus placebo in a Growers Association co-authored trial (7 men per arm) (Fukazawa et al., 2018). In HYPER-MASTIC, glucose fell more on placebo (Kalafati et al., 2026). Net: unconfirmed.

Magnitude: Fasting glucose fell by 4.5 mg/dL with 1 g/day crude mastic over 8 weeks (5.1 mg/dL in those with BMI above 25), adjusted for age, sex, BMI and baseline values; the abstract reports only the mastic-arm change, with no placebo-arm figure, so it is not compared between groups (Kartalis et al., 2016).

Lower Blood Pressure ⚠️ Conflicted

An Athens study reported acute blood-pressure lowering in hypertension (Kontogiannis et al., 2019); essential oil (indirect form) lowered systolic pressure within-group (Gioxari et al., 2023). In HYPER-MASTIC (106 well-controlled hypertensive adults, 1.5 or 2.8 g/day versus placebo, 3 months), 24-hour pressure did not differ (Kalafati et al., 2026). Net: unconfirmed.

Magnitude: 24-hour systolic blood pressure went from 122.88 to 126.4 mmHg on 1.5 g/day and from 123.44 to 124.12 mmHg on 2.8 g/day, versus 121.71 to 122.42 mmHg on placebo over 3 months; not compared between groups, and the groups’ changes did not differ significantly (Kalafati et al., 2026).

Improved Liver Markers ⚠️ Conflicted

In MAST4HEALTH, 98 people with obesity and NAFLD (non-alcoholic fatty liver disease) took 2.1 g/day or placebo for 6 months; liver-scan inflammation scores improved only with BMI above 35 (Amerikanou et al., 2021). Growers Association co-authored. Uncontrolled long-term use lowered liver enzymes (Triantafyllou et al., 2007). Net: subgroup-only signal.

Magnitude: Liver inflammation and fibrosis imaging scores improved versus placebo only in patients with BMI above 35; the abstract reports no outcome figure (Amerikanou et al., 2021).

Inflammatory Bowel Disease Activity ⚠️ Conflicted

In Kaliora’s group, 2.8 g/day for 3 months improved quality of life versus baseline in active IBD (inflammatory bowel disease) in a Growers Association co-authored trial (Papada et al., 2019) but did not reduce relapse in inactive IBD over 6 months (Papada et al., 2019). Net: no proven disease effect.

Magnitude: Relapse in 17.6% on mastic versus 23.5% on placebo over 6 months, not a significant difference (Papada et al., 2019).

Relief of Irritable Bowel Syndrome Symptoms

Irritable bowel syndrome (recurring abdominal pain with altered bowel habits) improved in a 55-person placebo-controlled trial of manufacturer-supplied drinks containing mastic water, a water-soluble resin by-product (Georgoulis et al., 2023); mastic water also eased functional dyspepsia in an unblinded crossover (Kleftaki et al., 2025). Indirect: water fraction, not resin.

Magnitude: Adequate symptom relief for at least 6 of 12 weeks in 83.3% (low dose) and 75.0% (high dose) on mastic water versus 50.0% and 36.4% on matching placebo drinks (Georgoulis et al., 2023).

Helicobacter pylori Eradication ⚠️ Conflicted

Mastic alone for 14 days eradicated H. pylori in about one-third of Chios pilot patients (Dabos et al., 2010) but in no UK patient (Bebb et al., 2003); added to quadruple therapy (a four-drug bismuth and antibiotic regimen), gains were not significant (Tulsian et al., 2026). Net: unreliable alone.

Magnitude: Eradication in 4/13 (1.05 g/day) and 5/13 (3.15 g/day) on mastic alone versus 10/13 on standard triple therapy (an acid reducer plus two antibiotics); no placebo group (Dabos et al., 2010).

Faster Stomach Emptying in Diabetic Gastroparesis

In an Indian trial, 38 people with diabetic gastroparesis (slow stomach emptying from diabetic nerve damage) took a stem-extract mastic product or levosulpiride, a prokinetic drug (one that speeds stomach emptying), for 8 weeks; both improved similarly (Singh et al., 2024). No placebo arm; possibly indirect form.

Magnitude: 4-hour gastric emptying rose by 20.6 percentage points on mastic versus 24.2 on levosulpiride, not a significant difference between groups (Singh et al., 2024).

Fresher Breath ⭕️ Not Central to Health & Longevity

Mastic mouthwash (Tsironi et al., 2023) and toothpaste (Alexiou et al., 2025) lowered hydrogen sulfide, the main bad-breath gas, versus placebo in two small Athens orthodontic trials. Indirect: rinse and paste forms, not chewing gum. This bears on oral comfort and social confidence rather than healthspan.

Magnitude: Hydrogen sulfide 72.34 ppb (parts per billion) lower than placebo mouthwash after 2 weeks, 95% confidence interval 8.48 to 136.27 (Tsironi et al., 2023).

Increased Saliva Flow in Dry Mouth

Smelling mastic resin raised saliva flow and mucus content in 41 chronic dry-mouth patients (Faruque et al., 2024), and chewing mastic raised saliva flow and pH more than tasteless wax (de Jong et al., 2026). Indirect route (scent) without a control group, plus one small chewing comparison.

Magnitude: Saliva flow rose versus each patient’s own unstimulated baseline (no control group); the abstract reports no outcome figure (Faruque et al., 2024).

Minor Wound Healing ⚠️ Conflicted

The EU monograph recognizes topical mastic for minor skin inflammation and wounds on tradition alone (EMA mastic page). In a 147-woman Iranian trial, mastic smoke (an indirect route) on episiotomy wounds (a surgical cut during childbirth) did not significantly improve healing or pain (Moudi et al., 2018). Net: unproven.

Magnitude: Wound-healing scale scores (lower is better) of 0.11, 0.15 and 0.15 on mastic smoke versus 0.21, 0.16 and 0.49 in controls at 3, 7 and 10 days, none significantly different; pain also did not differ (Moudi et al., 2018).

Nerve Protection ⚠️ Conflicted

RPh201, an injected mastic extract, was nerve-protective in animals and well tolerated in a first human study (Hazan et al., 2020). In a 22-person placebo-controlled trial after optic-nerve stroke, vision gains were non-significant (Rath et al., 2019); developer Regenera Pharma co-authored both. Indirect form and route. Net: unproven in people.

Magnitude: Vision improved by 15 or more letters in 4 of 11 eyes on RPh201 versus 1 of 8 on placebo after 26 weeks, not a significant difference, in an analysis added after the trial (Rath et al., 2019).

Speculative 🟨

Anticancer Activity

Mastic slowed prostate cancer cell growth (He et al., 2007), and oral mastic oil slowed colon tumor growth in mice (Spyridopoulou et al., 2017). Basis: cell and animal work only.

Antiviral Activity Against Influenza

Mastic blocked influenza A replication in cells and reduced illness and death in infected mice (Kim et al., 2021). Basis: laboratory and animal data only; no human studies.

Antioxidant and Immune-Signalling Effects

Mastic lowered oxidized LDL (Papada et al., 2018) and stabilized miR-155 (a small gene-regulating molecule that steers inflammatory T cells) (Amerikanou et al., 2021). Basis: unvalidated biomarkers, not outcomes.

Benefit-Modifying Factors

  • Genetic variants: In MAST4HEALTH, genome-wide analysis found several gene variants that changed antioxidant and inflammatory-marker responses to mastic (Kanoni et al., 2021); no variant is yet usable to predict benefit.
  • Baseline weight and metabolic status: Cholesterol and glucose effects were larger with BMI above 25 (Kartalis et al., 2016), and liver effects appeared only with BMI above 35 (Amerikanou et al., 2021).
  • Baseline blood pressure: People with already well-controlled blood pressure saw no further lowering, which the HYPER-MASTIC investigators attribute to a ceiling effect (Kalafati et al., 2026).
  • Sex: In a randomized dose study of adults over 50, a mastic solution lowered glucose only in men (Triantafyllou et al., 2007); no other trial has reported sex-specific results.
  • Pre-existing conditions: Signals are strongest in symptomatic functional dyspepsia (Dabos et al., 2010); people without digestive complaints have little evidence of digestive gain.
  • Age: Trials enrolled adults up to 80 years (Kalafati et al., 2026) and over 50 (Triantafyllou et al., 2007), but neither reported age-specific results; the EU monograph covers adults and older adults (EMA mastic page).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no replicated controlled trial has documented harm, and adverse-event reports come from small trials and patch-test case series.

Medium 🟥 🟥

No risk reaches Medium: the one controlled-trial harm signal, a secondary central-pressure measure, is contradicted by the same trial’s primary endpoints, and allergy data come from uncontrolled patch-test series.

Low 🟥

Allergic Contact Dermatitis

In a San Diego patch-test series, most patients with contact dermatitis (an itchy rash from touching an allergen) to Mastisol, a surgical skin adhesive, reacted to its gum mastic, possibly via linalool (a fragrance compound) (Shaw, 2021). Indirect: skin contact, not oral use.

Magnitude: 13 of 18 (72%) Mastisol-allergic patients were patch-test positive to gum mastic versus 1 of 250 (0.4%) patients without postoperative dermatitis; no placebo group (Shaw, 2021).

Possible Rise in Central Blood Pressure ⚠️ Conflicted

In HYPER-MASTIC, 24-hour central systolic pressure trended upward on 1.5 g/day, while the primary 24-hour blood-pressure endpoints did not differ from placebo (Kalafati et al., 2026). An earlier small trial reported improved blood-pressure measures (Kontogiannis et al., 2019). Net: likely chance.

Magnitude: 24-hour central systolic pressure went from 121.12 to 130.24 mmHg on 1.5 g/day and from 127 to 127.92 mmHg on 2.8 g/day, versus 124.23 to 124.23 mmHg on placebo over 3 months; not compared between groups, though the time-by-group interaction (groups changed differently over time) was significant (Kalafati et al., 2026).

Mild Stomach Discomfort ⚠️ Conflicted

One mastic-treated patient in the Indian gastroparesis trial had mild gastritis symptoms in week 1 (Singh et al., 2024), while the Chios cholesterol trial recorded no gastrointestinal adverse events (Kartalis et al., 2016). Net: uncommon and mild.

Magnitude: 1 of 19 on mastic reported mild gastritis symptoms; the levosulpiride comparison arm reported loose stools, sleepiness and fatigue, without counts in the text (Singh et al., 2024).

Speculative 🟨

Cross-Reactive Allergy

Pollen hypersensitivity is a listed contraindication (Drugs.com mastic monograph); pistachio, cashew or mango allergy may extend to mastic (WebMD). Serum screening found IgE (allergy-type antibodies) to mastic (Vojdani & Vojdani, 2015). Basis: cautions and antibody screening.

Jaw Muscle and Joint Strain

Raw mastic is firmer than ordinary gum; long chewing sessions could overload jaw muscles and the temporomandibular joint (jaw hinge). Basis: mechanistic reasoning and anecdotal reports only.

Liver Enlargement and Tumor Promotion in Rats

Rats fed mastic for 13 weeks had dose-related liver enlargement without tissue damage (Kang et al., 2007); 1% dietary mastic promoted precancerous liver lesions after a carcinogen (Doi et al., 2009). Basis: animal data only.

Untested Reproductive and Long-Term Safety

The EU monograph notes that reproductive, genotoxicity (damage to genetic material) and carcinogenicity (cancer-causing potential) tests have not been performed (EMA mastic page); human trials lasted at most 18 months. Basis: absence of data.

Risk-Modifying Factors

  • Genetic variants: No genetic variant is known to change mastic’s side-effect risk; no study has tested how genes affect reactions to mastic.
  • Baseline biomarkers: People with treated, well-controlled hypertension showed no lowering and possibly a small upward drift (Kalafati et al., 2026); no laboratory marker predicts intolerance.
  • Sex: No sex differences in adverse effects have been reported; pregnancy and breastfeeding lack safety data (EMA mastic page).
  • Pre-existing allergy: Known allergy to Mastisol, fragrances or linalool raises the chance of reacting to mastic (Shaw, 2021); pollen hypersensitivity is a listed contraindication in a natural-product monograph (Drugs.com mastic monograph).
  • Age: The EU monograph does not recommend oral use under 18 (EMA mastic page); older adults on multiple medications face untested combinations rather than known harms.

Key Interactions & Contraindications

  • Proton pump inhibitors (acid-reducing drugs such as pantoprazole, omeprazole): Caution. With pantoprazole, mastic eradicated H. pylori in 0 of 13 patients versus 4 of 13 on mastic alone (Dabos et al., 2010); acid suppression may blunt anti-H. pylori effects.
  • H. pylori antibiotic regimens (bismuth, tetracycline, metronidazole): Monitor. Adding mastic to bismuth quadruple therapy did not increase adverse effects in a randomized trial (Tulsian et al., 2026); no interaction found.
  • Glucose-lowering drugs (metformin; sulfonylureas (drugs that make the pancreas release insulin) such as gliclazide; insulin): Monitor (theoretical). Possible additive glucose lowering suggested by small trials; separate monitoring of glucose when starting mastic avoids unexpected lows.
  • Cholesterol-lowering drugs (statins (drugs that block cholesterol production) such as atorvastatin): Monitor (theoretical). Possible small additive cholesterol effect; no human interaction study exists, and statins’ effect dwarfs mastic’s.
  • Drugs metabolized by CYP1A2 (caffeine, theophylline, clozapine): No interaction expected (theoretical). Mastic did not induce CYP1A1/CYP1A2 in rats (Katsanou et al., 2014); human data are lacking.
  • Over-the-counter antacids and acid reducers (calcium carbonate, famotidine): Caution (theoretical). By analogy with the pantoprazole finding, reduced stomach acid might lower mastic’s antibacterial action; timing separation is untested.
  • Supplements with additive metabolic effects (berberine, red yeast rice, chromium): Monitor (theoretical). Additive lowering of glucose or cholesterol is possible; lipids and glucose rechecked at 8–12 weeks reveal combined effects.
  • Other chewing gums and topical adhesives containing mastic (Mastisol): Caution (theoretical). Combined skin and oral exposure could add to sensitization (development of allergy) in fragrance-allergic people; gum mastic caused most reactions in Mastisol-allergic patients (Shaw, 2021).

Populations who should avoid Mastic Gum:

  • People with hypersensitivity to mastic, the listed contraindication of the EU monograph (EMA mastic page), including those patch-test positive to gum mastic or Mastisol (Shaw, 2021)
  • Pregnant or breastfeeding women, for whom the EU monograph does not recommend use in the absence of safety data (EMA mastic page)
  • Children and adolescents under 18 years for oral use, per the EU monograph (EMA mastic page)
  • People with pollen hypersensitivity, listed as a contraindication by a natural-product monograph (Drugs.com mastic monograph)

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

  • Skin patch test before topical or prolonged use: dermatologist patch testing, the method that identified gum mastic allergy in a case series (Shaw, 2021), detects contact allergy before broader exposure, mitigating allergic contact dermatitis.
  • Stop at first allergic sign: any rash, itching, lip swelling or wheezing is a reason to stop and seek medical advice, preventing escalation of a hypersensitivity reaction (EMA mastic page).
  • Two-week symptom rule: the EU monograph advises consulting a doctor if indigestion persists beyond 2 weeks of use, preventing a missed ulcer, H. pylori infection or cancer (EMA mastic page).
  • Confirm H. pylori clearance with testing: a urea breath test (a non-invasive test for active infection) at least 4 weeks after treatment prevents relying on mastic alone when it fails, mitigating persistent infection (Dabos et al., 2010).
  • Home blood-pressure checks: weekly home readings for the first month detect the possible small rise in central pressure seen in one trial (Kalafati et al., 2026), mitigating unnoticed blood-pressure drift.
  • Glucose monitoring with diabetes drugs: checking fasting glucose for the first 2–4 weeks mitigates possible additive lowering with glucose-lowering medication.
  • Moderate chewing sessions: limiting raw-resin chewing to about 15–30 minutes at a time mitigates jaw muscle and joint strain.

Therapeutic Protocol

Timing, cycling and titration steps below reflect common practice unless cited.

  • EU traditional-use dose: 0.5–1 g powdered mastic twice daily (1–2 g/day) for mild indigestion in adults and older adults, per the EU herbal monograph (EMA mastic page).
  • Functional dyspepsia trial regimen: 350 mg three times daily for 3 weeks (Dabos et al., 2010); 1.4 g/day for 4 weeks in a later crossover trial (Kleftaki et al., 2025).
  • H. pylori regimen: 350 mg or 1.05 g three times daily for 14 days (Dabos et al., 2010); advocated by Dr. Jonathan Wright and described by Chris Kresser as a possible first-line therapy (Kresser, 2010).
  • Metabolic and bowel-inflammation regimens: 1 g/day crude mastic (330 mg three times daily) for cholesterol (Kartalis et al., 2016); 2.1 g/day for fatty liver (Kanoni et al., 2021); 2.8 g/day for IBD (Papada et al., 2019).
  • Manufacturer regimen (alternative approach): one marketed product advises 4 × 250 mg capsules before bed for 2 weeks, then 2 daily, as reported by Drugs.com (Drugs.com mastic monograph).
  • Chewing for oral health: chewing raw mastic gum after meals, as in plaque trials (Takahashi et al., 2003); trials did not standardize amounts.
  • Time of day: trials dosed with meals or spread across the day; no trial compared morning versus evening dosing.
  • Half-life: no formal half-life exists; terpenes peak in blood at 2–4 hours, and antioxidant effects persisted to 24 hours after one dose (Papada et al., 2018).
  • Single versus split dosing: most trials split the daily dose two or three times, matching the short peak; no trial compared once-daily dosing.
  • Genetic variants: no variant guides dose choice; findings on how genes shape the response to mastic remain exploratory (Kanoni et al., 2021).
  • Sex: no sex-specific dosing exists; one study found glucose lowering only in men (Triantafyllou et al., 2007).
  • Age: adult trials included people up to 80 at standard doses (Kalafati et al., 2026); oral use under 18 is not recommended (EMA mastic page).
  • Baseline biomarkers: higher BMI (above 25) predicted larger cholesterol and glucose responses (Kartalis et al., 2016); confirmed H. pylori status guides use for stomach complaints.
  • Pre-existing conditions: functional dyspepsia is the best-supported indication; in IBD trials mastic was mostly added to stable standard medication (Papada et al., 2019).

Discontinuation & Cycling

  • Short-term by design: EU traditional use is short-term, with medical review if symptoms persist beyond 2 weeks (EMA mastic page); H. pylori regimens ran 14 days.
  • Longer metabolic use: trials ran 8 weeks to 18 months (Triantafyllou et al., 2007) without safety signals; lifelong use is untested.
  • Withdrawal effects: none reported in any trial, and no dependence or rebound mechanism is known.
  • Tapering: not needed; mastic can be stopped at once.
  • Cycling: no evidence that cycling preserves efficacy; pausing after 1–3 months to reassess symptoms or lipid results is a common-practice option.

Sourcing and Quality

  • Botanical origin: Genuine Chios mastic comes from Pistacia lentiscus var. chia grown in southern Chios (Pachi et al., 2020); resins from other Pistacia species (such as Pistacia atlantica) have different chemistry.
  • Pharmacopoeial quality: The EU monograph specifies powdered resin meeting the European Pharmacopoeia mastic standard (EMA mastic page); labels citing this standard or a certificate of analysis indicate verified identity.
  • Form matters: Crude resin, polymer-free extracts, essential oil and mastic water are different products; essential-oil trials (Kartalis et al., 2024; Gioxari et al., 2023) do not establish effects of the resin.
  • Third-party testing: ConsumerLab has published no dedicated mastic product review; independent identity and contaminant testing (e.g., USP (United States Pharmacopeia) or NSF (an independent certifier) verification, or published certificates of analysis) is the main safeguard.
  • Reputable brands: Widely sold capsule brands include Jarrow Formulas and Allergy Research Group; Chios-produced resin tears are sold for chewing.

Practical Considerations

  • Time to effect: Dyspepsia trials measured relief at 3–4 weeks (Dabos et al., 2010); cholesterol and glucose changes were assessed at 8 weeks (Kartalis et al., 2016); oral bacterial effects appear within hours of chewing (Aksoy et al., 2007).
  • Common pitfalls: Treating mastic as a reliable H. pylori cure, confusing essential oil or mastic water with resin, and assuming metabolic benefits proven in healthy people.
  • Regulatory status: The EU lists mastic as a traditional herbal medicine for mild indigestion and minor skin inflammation (EMA mastic page).
  • Funding structure: No single company owns whole mastic resin, so large trials are rare; most come from a few Greek academic groups, often with producer co-authors, and the one industry drug program, Regenera Pharma’s injected extract RPh201, was terminated without posted results.
  • Cost and access: Mastic is widely available online at moderate cost; supply is limited by Chios production.

Interaction with Foundational Habits

  • Sleep: No direct interaction (none). No trial measured sleep, and mastic has no known sedating or stimulating action; evening dosing in some product regimens has not been linked to sleep complaints.
  • Nutrition: Indirect, possibly potentiating. Trials dosed mastic with meals; effects on blood fats were seen without diet change. Iron rose in the IBD trial (Papada et al., 2019) and haemoglobin in the gastroparesis trial (Singh et al., 2024); no nutrient depletion is known.
  • Exercise: Potentiating. In Japanese men, mastic plus 30 minutes of exercise three times weekly lowered insulin resistance earlier than mastic alone (Fukazawa et al., 2018); no timing around workouts has been studied.
  • Stress management: None established. Mastic acids inhibit 11β-HSD1 in the laboratory, which could in theory lower tissue cortisol (Vuorinen et al., 2015); no human study has measured cortisol or stress responses.

Monitoring Protocol & Defining Success

Before starting, a baseline record establishes a reference point: digestive symptoms over two weeks, lipid panel and fasting glucose for anyone using mastic for metabolic goals, a urea breath test when H. pylori is suspected, liver enzymes, and home blood-pressure readings. People with fragrance or adhesive allergy benefit from a skin patch test.

Ongoing monitoring follows the trial timelines: symptom review at 2 and 4 weeks (with medical review if indigestion persists beyond 2 weeks), a urea breath test 4–6 weeks after an H. pylori course, lipids and fasting glucose at 8–12 weeks, then every 6–12 months during continued use. Blood pressure is checked weekly for the first month and then at routine visits. Success means sustained symptom relief or a measurable lipid or glucose change versus baseline; absent change by 12 weeks suggests no benefit.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Total cholesterol No established target; track change from own baseline Expected to change (may fall) Fasting not required in most labs; repeat at 8–12 weeks; LDL was unchanged at 1 g/day in one trial (Kartalis et al., 2016)
Fasting glucose 70–99 mg/dL (standard reference range) Expected to change; safety check with diabetes drugs 8–12 hour fast; morning draw; pair with HbA1c (3-month average blood sugar) in diabetes
Urea breath test for H. pylori No established target; track conversion from positive to negative after a course Expected to change if used against H. pylori Stop acid-reducing drugs 2 weeks and antibiotics 4 weeks before testing; used at least 4 weeks after a course
ALT 7–56 U/L (standard reference range; varies by laboratory) Expected to change (fell in long-term use) ALT: alanine aminotransferase, a liver enzyme that rises in blood when liver cells are damaged; pair with AST (aspartate aminotransferase, another liver-damage enzyme) and GGT (gamma-glutamyl transferase, a bile-duct enzyme) (Triantafyllou et al., 2007)
Home blood pressure No established target for mastic use; track change from own baseline Safety check (possible small rise) Seated morning readings, averaged over a week; the trial signal came from 24-hour ambulatory central pressure (Kalafati et al., 2026)

Qualitative markers:

  • Upper-abdominal pain, fullness, bloating and heartburn frequency
  • Bowel habit and abdominal comfort in irritable bowel syndrome or IBD
  • Breath freshness and gum bleeding on brushing
  • Mouth dryness
  • Skin reactions, itching or jaw soreness

Emerging Research

  • Mastic water for dyspepsia (MASTIQUA-D): A recruiting 60-person double-blind trial tests 600 mL/day of a drink with 0.2% mastic water for 3 months against placebo, with dyspepsia severity as primary endpoint (NCT06909890). A positive result would extend dyspepsia benefit to the water fraction; a null result would confine it to whole resin.
  • Mastiha oil for high triglycerides: A 100-person trial of one daily mastic-oil capsule for 3 months (NCT06323252) passed its registered completion date (October 2025); status unknown, no results posted.
  • Completed trials with published results: The dyspepsia crossover (NCT05687539; Kleftaki et al., 2025), completed 2024, is cited in the Benefits items. The irritable bowel trial of mastic-water drinks (NCT04893499; Georgoulis et al., 2023), completed 2022, reported lower symptom scores than placebo and is cited in the Benefits items; it is not indexed in PubMed.
  • Mastic-derived nerve drug: After a 22-person phase 2a trial found non-significant vision gains (Rath et al., 2019), a 165-person phase 2 trial of RPh201 in optic-nerve stroke (NCT03547206) was terminated in 2020 with no results posted, leaving nerve protection unconfirmed.
  • Adjunct H. pylori therapy: A pilot found non-significant eradication gains when mastic was added to quadruple therapy (Tulsian et al., 2026), prompting calls for adequately powered trials (Zavos, 2026); a large trial could confirm or retire this use.
  • Higher-risk cardiovascular groups: HYPER-MASTIC found no blood-pressure effect but vascular gene-expression changes in higher-risk participants (Kalafati et al., 2026); trials in uncontrolled hypertension could strengthen or weaken the cardiometabolic case.
  • Longevity endpoints: No study has measured mastic’s effect on mortality, biological-age markers or age-related disease incidence; a 2024 review describes the cardiometabolic trials as limited, with mixed results (Blomquist & Fernandez, 2024), leaving independent replication as the key open area.

Conclusion

Mastic gum is a Greek tree resin long used as a stomach and mouth remedy, now sold as chewing gum, powder and capsules. For health-focused adults, its most credible use is easing recurring indigestion that has no visible cause, supported by one well-controlled study and a weaker later one, and accepted by the European medicines regulator for its long traditional use. Chewing it may briefly reduce plaque and mouth bacteria, and one old study suggested faster healing of small-intestine ulcers.

The claims most relevant to a long healthy life are weaker. Effects on cholesterol, blood sugar, fatty liver and bowel inflammation are small, differ from study to study, or appear only in some people, and the most careful recent blood-pressure study found no lowering. Its reputation for clearing the main ulcer-causing stomach bacterium rests on mixed results. Effects against cancer and viruses rest on laboratory and animal work, and nerve protection, studied only by the company developing a mastic-based drug, is unproven.

Safety looks favorable: studies report few side effects, and the main documented problem is skin allergy in people already allergic to a surgical skin glue that contains mastic. Information on pregnancy, long-term use and medicine combinations is thin.

The research base is small, mostly short and concentrated in a few Greek groups; many studies were co-written by researchers tied to the island’s mastic growers’ cooperative, which gains from wider use. Mastic emerges as a low-risk aid for digestion and the mouth whose value for longevity is unproven.

Top - Benefits - Risks - Protocol